## **REMARKS**

Claims 1, 8 and 12 to 15 are present.

The Examiner points out that "Claims 8 and 15 need to be placed in independent form and can then be allowed. The remaining claims should formally be cancelled."

The subject matter of Claim 8 has been combined with Claim 1 as indicated by the above amendment to Claim 1. In view of this amendment it is believed that Claim 1 is now in condition for allowance.

Claim 15 is dependent upon Claim 1 and thus is in condition for allowance.

It is believed that Claim 12 directed to a pharmaceutical composition which includes the compound as defined in Claim 1 is also in condition for allowance.

Claims 13 and 14 depend from Claim 12 and therefore it is submitted that Claims 13 and 14 are in condition for allowance.

All other claims have been cancelled. However, Applicant reserves the right to file divisional applications directed to non-elected inventions.

In view of the foregoing, it is believed that Claims 1, 8 and 12 to 15 are in condition for allowance.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: Aug. 23 2603

Burton Rodney Attorney for Applicant Reg. No. 22,076